Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
All,
this was my last posting on this board. I am done with AMRN. This company is only producing bad news, and they do not understand even the basics of running a business.
Now that I am out the stock price can go upwards. GL to all.
Scripts for week ending 12/02/2021
Below the updated script numbers. I included scripts for Lovaza (incl. Generic, though not sure I captured all suppliers) - for reference. I'll leave it to RAF and Sam to comment on plausibility of the figures.
Vascepa
TRx: 81'787 (-0.96%)
NRx: 37'991 (-4.28%)
Generic Vascepa
TRx: 10'833 (+48.91%)
NRx: 6'549 (+49.29%)
Generic Lovaza
TRx: 62'417 (+1.08%)
NRx: 31'333 (+0.00%)
Apologies again. I have a script running, and it failed w/o error message. And I did not immediately double check.
Apologies. Was wrong.
Scripts for week ending 12/02/2021
Below the updated script numbers. I included scripts for Lovaza (incl. Generic, though not sure I captured all suppliers) - for reference. I'll leave it to RAF and Sam to comment on plausibility of the figures.
Vascepa
TRx: 82'579 (-1.19%)
NRx: 39'689 (-0.39%)
Generic Vascepa
TRx: 7'275 (-21.35%)
NRx: 4'386 (-19.62%)
Generic Lovaza
TRx: 61'750 (-0.13%)
NRx: 31'333 (-2.34%)
I always reply to the previous post. See post# 320531 for 22/01.
Scripts for week ending 29/01/2021
Below the updated script numbers. I included scripts for Lovaza (incl. Generic, though not sure I captured all suppliers) - for reference. I'll leave it to RAF and Sam to comment on plausibility of the figures.
Vascepa
TRx: 83'571 (-1.47%)
NRx: 39'844 (-0.82%)
Generic Vascepa
TRx: 9'250 (+1.83%)
NRx: 5'457 (+3.47%)
Generic Lovaza
TRx: 61'833 (+1.78%)
NRx: 32'083 (+2.39%)
It is algos reading topline. Primary endpoint was not met. Should reverse later. Though in this market you'd never know
MTNB - FAIL
Another bit of good news.
https://ca.finance.yahoo.com/amphtml/news/matinas-biopharma-announces-topline-results-110000148.html?__twitter_impression=true
Primary endpoint of percent change from baseline to end of treatment in triglycerides in the pharmacodynamic population did not meet statistical significance over Vascepa®
Scripts for week ending 22/01/2021
Below the updated script numbers. I included scripts for Lovaza (incl. Generic, though not sure I captured all suppliers) - for reference. I'll leave it to RAF and Sam to comment on plausibility of the figures.
Vascepa
TRx: 84'819 (-3.87%)
NRx: 40'174 (-3.54%)
Generic Vascepa
TRx: 9'083 (+47.10%)
NRx: 5'274 (+43.87%)
Generic Lovaza
TRx: 60'750 (-4.08%)
NRx: 31'333 (-4.81%)
Scripts for week ending 15/01/2021
Below the updated script numbers. I included scripts for Lovaza (incl. Generic, though not sure I captured all suppliers) - for reference. I'll leave it to RAF and Sam to comment on plausibility of the figures.
Vascepa
TRx: 88'229 (+2.69%)
NRx: 41'650 (+7.18%)
Generic Vascepa
TRx: 6'175 (+13.56%)
NRx: 3'666 (+24.52%)
Generic Lovaza
TRx: 63'333 (-0.52%)
NRx: 32'917 (+3.13%)
Scripts for week ending 08/01/2021
Below the updated script numbers. I included scripts for Lovaza (incl. Generic, though not sure I captured all suppliers) - for reference. I'll leave it to RAF and Sam to comment on plausibility of the figures.
Note that this we are coming out of a short week.
Vascepa
TRx: 85'920 (+2.81%)
NRx: 38'860 (+14.60%)
Generic Vascepa
TRx: 5'437 (+41.65%)
NRx: 2'944 (+60.00%)
Generic Lovaza
TRx: 63'667 (+3.38%)
NRx: 31'917 (+10.69%)
Ask CaptBeer. He compiles some charts.
Scripts for week ending 01/01/2021
Below the updated script numbers. I included scripts for Lovaza (incl. Generic, though not sure I captured all suppliers) - for reference. I'll leave it to RAF and Sam to comment on plausibility of the figures.
Note that this was a short week.
Vascepa
TRx: 83'572 (+3.46%)
NRx: 33'910 (-10.17%)
Generic Vascepa
TRx: 3'839 (-12.92%)
NRx: 1'840 (-20.40%)
Generic Lovaza
TRx: 61'583 (+5.57%)
NRx: 28'833 (-6.23%)
No idea. I am just the messenger. Happy new year.
Scripts for week ending 12/25/2020
Below the updated script numbers. I included scripts for Lovaza (incl. Generic, though not sure I captured all suppliers) - for reference. I'll leave it to RAF and Sam to comment on plausibility of the figures.
Note that this was a short week. Happy new year.
Vascepa
TRx: 80'775 (-10.79%)
NRx: 37'749 (-11.54%)
Generic Vascepa
TRx: 4'408 (-44.68%)
NRx: 2'311 (-42.59%)
Generic Lovaza
TRx: 58'333 (-15.66%)
NRx: 30'750 (-18.54%)
Scripts for week ending 12/11/2020
Below the updated script numbers. I included scripts for Lovaza (incl. Generic, though not sure I captured all suppliers) - for reference. I'll leave it to RAF and Sam to comment on plausibility of the figures.
Note that there was a typo in the NRx for Vascepa last week, which overstated scripts by 3k. Apologies for any inconveniences.
Vascepa
TRx: 88'094 (+0.72%)
NRx: 39'508 (-6.09%)
Generic Vascepa
TRx: 7'706 (+51.94%)
NRx: 4'055 (+43.25%)
Generic Lovaza
TRx: 65'417 (-0.76%)
NRx: 32'833 (-1.01%)
Multiple failures in COVID studies announced today: e.g. Novartis RUXCOVID failed in COVID-19:
https://www.novartis.com/news/media-releases/novartis-provides-update-ruxcovid-study-ruxolitinib-hospitalized-patients-covid-19
Scripts for week ending 12/04/2020
Below the updated script numbers. I included scripts for Lovaza (incl. Generic, though not sure I captured all suppliers) - for reference. I'll leave it to RAF and Sam to comment on plausibility of the figures.
Vascepa
TRx: 86'583 (+21.73%)
NRx: 42'070 (+37.99%)
Generic Vascepa
TRx: 5'072 (-3.85%)
NRx: 2'831 (+1.65%)
Generic Lovaza
TRx: 65'917 (+22.26%)
NRx: 33'167 (+27.16%)
Scripts for week ending 11/27/2020
Below the updated script numbers. I included scripts for Lovaza (incl. Generic, though not sure I captured all suppliers) - for reference. I'll leave it to RAF and Sam to comment on plausibility of the figures.
Note that this was a short week (Thanksgiving)
Vascepa
TRx: 71'849 (-10.45%)
NRx: 30'488 (-19.46%)
Generic Vascepa
TRx: 5'275 (-30.22%)
[I]NRx: 2'785 (-27.78%)
Generic Lovaza
TRx: 53'917 (-14.19%)
NRx: 26'083 (-20.96%)
Because they are not allowed to reference R-IT label. If the do - in any way - they'd be infringing on that indication, as it is not within the skinny label that they are approved for.
Doesn't sound to bad. Eiter Hikma updates label to include additional warnings from R-IT label, or - as stated in the case of Guvenoz v. Target Corp (last paragraph in the link you attached) - the legal duty owed to consumers would be to change the formula, change the label or stop selling the drug altogether. I.e. if Hikma does the prior, they'd infringe on R-IT label, if they don't, all it takes would be on edeath who has switched from Vascepa to gV to sue the shit out of Hikma.
Nope. Generics are obviously infringing. But if nobody takes them into courts it doesn't matter.
Scripts for week ending 11/20/2020
Below the updated script numbers. I included scripts for Lovaza (incl. Generic, though not sure I captured all suppliers) - for reference. I'll leave it to RAF and Sam to comment on plausibility of the figures.
Scripts taking another hit from generics, while the sales force is failing to grow the market. Disappointing to say the least.
Vascepa
TRx: 80'238 (-5.29%)
[I]NRx: 37'855 (-2.75%)
Generic Vascepa
TRx: 7'559 (+83.58%)
NRx: 4'118 (+69.56%)
Generic Lovaza
TRx: 62'833 (-1.69%)
NRx: 33'00 (-0.75%)
Do you know if that has happened already to one of your patients?
Doesn't take into account that the generic has not R-IT on the label. Therefore some party is infringing - directly or indirectly. And AMRN needs to take the weakest party to the court. If it is the pharmacies, so be it.
Sure you don't. But if it is insurers - they induce infringement; it it is state law, policy makers induce infringement. In the case of Vascepa it is pretty obvious that someone is to be held liable. At least in a constitutional state. Obviously not in a banana republic which the US have become.
So they should not switch.
There is still too many of them. Haha.
I think this may be explained by pharmacies waiting for generic API. As described by other users.
Hikma already took out the full high trig population. Any additional scripts would be infringing in R-IT scripts.
Scripts for week ending 11/13/2020
Below the updated script numbers. I included scripts for Lovaza (incl. Generic, though not sure I captured all suppliers) - for reference. I'll leave it to RAF and Sam to comment on plausibility of the figures.
Vascepa
TRx: 84'723 (-10.15%)
NRx: 38'924 (-9.35%)
Generic Vascepa
TRx: 4'118 (+ %)
NRx: 2'274 (+ %)
Generic Lovaza
TRx: 63'917 (+0.13%)
NRx: 33'250 (+0.25%)
The good stuff for the Chinese and European oatients, the crap for the US patients. And they even oay-up for this. Can't make shit up.
BAKER BROTHERS HOLD 32MM SHARES ACCORDING TO LATEST 13F Down from 34MM in last filing.
What we have done does not really correspond to the normal manners of scientific practice. In view of the p-value of the REDUCE-IT studies, to speak of a false positive result implies that Dr. Dr. Batth is assuming falsification.
What motivates him to make such a blatant statement?
Sorry guys. These 7k are NOT normalized.
Scripts for week ending 11/06/2020
Below the updated script numbers. I included scripts for Lovaza (incl. Generic, though not sure I captured all suppliers) - for reference. I'll leave it to RAF and Sam to comment on plausibility of the figures.
NOTE: Generics have launched with 7k scripts. I will incorporate starting next week.
Vascepa
TRx: 94'290 (+0.80%)
NRx: 42'939 (-0.28%)
Generic Lovaza
TRx: 63'833 (+1.06%)
NRx: 33'167 (+1.02%)
Couldn't AMRN simply change Vacepas composition to match the generics "quality". Should be ok, as nobody cares anyways.